Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 35Carcinoma, Hepatocellular 28Stomach Neoplasms 12Neoplasm Metastasis 12Nasopharyngeal Carcinoma 11Neoplasms 10Esophageal Neoplasms 10Melanoma 8Esophageal Squamous Cell Carcinoma 8Colorectal Neoplasms 8Recurrence 7Lung Neoplasms 7Breast Neoplasms 7Biliary Tract Neoplasms 7Triple Negative Breast Neoplasms 6Small Cell Lung Carcinoma 5Rectal Neoplasms 5Pancreatic Neoplasms 5Head and Neck Neoplasms 5Cholangiocarcinoma 5Squamous Cell Carcinoma of Head and Neck 4Locally Advanced Rectal Cancer 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Advanced NSCLC 4Urinary Bladder Neoplasms 3Sarcoma 3Liver Neoplasms 3Leukemia, Myeloid, Acute 3Hyperthermia 3

Interventions

Carboplatin 5pembrolizumab 4Trastuzumab 4Oxaliplatin 4Fluorouracil 4Cyclophosphamide 4Radiotherapy 3Paclitaxel 3Endoscopy 3Docetaxel 3Cytarabine 3Chemoradiotherapy 3Capecitabine 3toripalimab 2Tretinoin 2Surgical Procedures, Operative 2Standard of Care 2Observation 2Neoadjuvant Therapy 2Metformin 2Magnetic Resonance Imaging 2Leucovorin 2Irinotecan 2Immunotherapy 2Immune Checkpoint Inhibitors 2Epirubicin 2Drug Therapy 2Doxorubicin 2Cisplatin 2Blood Specimen Collection 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Pathologic Complete Response × Immune Checkpoint Inhibitors × Clear all
NCT06647680 2026-03-06

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer(CONTROL-01)

The Affiliated Hospital of Qingdao University

Phase 2 Recruiting
35 enrolled
Gastrointestinal

Pathologic Complete Response, Rectal Neoplasms

NCT06889402 2025-03-21

Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Not yet recruiting
600 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Pathologic Complete Response, Esophageal Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡